Atherothrombosis: role of chronic vascular inflammation
Abstract
The results of our studies and the data of scientific literature indicate on the significant role of vascular inflammation. The authors suggest considering of the structural and functional damage of endothelium and signs of vascular inflammation observed in atherothrombosis in the context of common pathologic process – vascular inflammatory reaction (response). The modern approaches for pharmacological prophylaxis of any variants of complications of atherothrombosis are discussed.
About the Authors
G. I. Kostyuchenko
RAMS; Regional state healthcare institution «Altai Regional Clinical Hospital»
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
Boris Bogatkov str., 175/1
Novosibirsk
656045
Lyapidevsky str., 1
Barnaul
Yu. P. Nikitin
RAMS
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
Boris Bogatkov str., 175/1
Novosibirsk
D. D. Arzamastsev
Regional state healthcare institution «Altai Regional Clinical Hospital»
Russian Federation
Russian Federation
656045
Lyapidevsky str., 1
Barnaul
D. A. Ananiev
Regional state healthcare institution «Altai Regional Cardiological Dispensary»
Russian Federation
Russian Federation
656055
46 Malakhov Street
Barnaul
A. D. Tsalikhin
Ministry of Health and Social Development of the Russian Federation
Russian Federation
Russian Federation
State budgetary educational institution of higher professional education «Altai State Medical University»
656038
avenue. Lenin, 40
Barnaul
L. A. Kostyuchenko
Ministry of Health and Social Development of the Russian Federation
Russian Federation
Russian Federation
State budgetary educational institution of higher professional education «Altai State Medical University»
656038
avenue. Lenin, 40
Barnaul
References
1. Костюченко Г. И. Гипергомоцистеинемия и коронарная болезнь сердца как проблема пожилого возраста / Г. И. Костюченко, З. С. Баркаган // Клин. геронтол. – 2003. – № 5. – С. 9–12.
2. Virchow R. Gesammelte Abhandlungen zur Wissenshaftlichen Medicin. Frankfurt: Meidinger, 1856.
3. Hans J., Corti R., Hutter R. et al. The interplay between inflammation and thrombosis in atherosclerosis // Acute Coronary Syndromes. 2002. Vol. 4. P. 71–78.
4. Карпов Ю. А. Воспаление и атеросклероз: состояние проблемы и нерешенные вопросы / Ю. А. Карпов, Е. В. Сорокин, О. А. Фомичева // Сердце. – 2003. – Т. 2 (4). – С. 190–192.
5. Сапина А. И. Влияние адгезивных и острофазных белков плазмы на течение и прогноз острого коронарного синдрома: Авторф. дис... канд. мед. наук / А. И. Салина. – М., 2003. – 21 с.
6. Anderson T. G. Assessment and treatment of endothelial dysfunction in humans // J. Amer. Coll. Cardiol. 1999. Vol. 34. P. 631–637.
7. Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation // Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 1882. Vol. 90. P. 261–332.
8. Bonetti P. O., Lerman L. O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk // Athe roscler. Thromb. Vasс. Biol. 2003. Vol. 23. P. 168–175.
9. Esmon C. T. Inflammation and thrombosis // J. Thromb. Haemost. 2003. Vol. 1 (7). P. 1343–1348.
10. Volpato S., Guralnik J. M., Ferrucci L. et al. Cardiovascular disease, Interleukin-6, and risk of mortality in older women: The Women’s health and Aging Study // Circulation. 2001. Vol. 103. P. 947–953.
11. Davies M. J. Stability and instability: two faces of coronary atherosclerosis // Circulation. 1996. Vol. 94. P. 2013–2020.
12. Schachinger V., Zeiher A. M. Coronary artery disease and endothelial function. In: Pan Vascular medicine / Eds. P. Lancer, E. J. Tonol. Berlin c. a: Springer Verlag, 2002. P. 887–912.
13. Алексеева И. А. Белки острой фазы и рецидив стенокардии после успешной коронарной ангиопластики / И. А. Алексеева [и др.] // Терапевт. архив. – 2002. – № 34. – С. 42–46.
14. Баркаган З. С. Место антитромбоцитарных средств в комплексной профилактике и терапии атеротромбоза / З. С. Баркаган. – Сибирская науч.-практ. конф. по актуальным вопросам фармакотерапии. – Новосибирск, 1999. – C. 7–22.
15. Павликова Е. П. Клиническое значение интерлейкина-6 и фактора некроза опухоли при ишемической болезни сердца / Е. П. Павликова, И. А. Мерай // Кардиология. – 2003. – № 8. – С. 68–72.
16. Esmon C. T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins // J. Exp. Med. 2002. Vol. 196. P. 561–564.
17. Frenette P. S., Wagner D. D. Adhesion molecules – Part I and Part II // N. Engl. J. Med. 1996. Vol. 334. P. 1526–1529; Vol. 335 P. 43–45.
18. Haverkate F., Thompson S. G., Руке S. D. et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina // Lancet. 1997. Vol. 349. P. 462–466.
19. Heverkate F., Thompson S. G., Руке S. D. et al. Production of C-reative protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and disabilities Angina Pectoris Study Group // Lancet. 1997. Vol. 349. P. 462–466.
20. Kocnig W., Sund M., Frohlich M. et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy midde-aged men. Results from the MONICA Augsburg Cohort Study, 1984-97 // Circulation. 1999. Vol. 99. P. 237–242.
21. Liuzzo G., Biasucci L. M., Gallimore J. R. et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina // N. Engl. J. Med. 1994. Vol. 331. P. 417–424.
22. Morrow D. A., Rifai D., Antman E. M. et al. C-reactive protein is a patent predictor of acute coronary syndromes // J. Amer. Coll. Cardiol. 1998. Vol. 31. P. 1460–1465.
23. Ridker P. M., Cushman M., Stampfer M.J. et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease // Circulation. 1998. Vol. 97. P. 425–428.
24. Ridker P. M. Role of inflammation in the development of atherosclerosis // Europ. Heart J. 2000. Vol. 2 (Suppl. 01). P. 57–59.
25. Ridker P. M., Rifai N., Stampfer M. J. et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men // Circulation. 2000. Vol. 101. P. 1767–1772.
26. Ridker P. M. High-sensitive C-reative protein // Circulation. 2001. Vol. 103. P. 1837–1818.
27. Ruggeri Z. M. Von Willebrand factor, platelets and endothelial cell interaction // J. Thromb. Haemost. 2003. Vol. 1 (7). P. 1335–1342.
28. Баркаган З. С. Гипергомоцистеинемия как самостоятельный фактор риска поражения и тромбирования кровеносных сосудов / З. С. Баркаган, Г. И. Костюченко, Е. Ф. Котовщикова // Патол. кровообр. и кардиохирургия. – 2002. – № 1. – С. 65–71.
29. Seghatshan M. G., Samama M. M., Hecker S. P., eds. Hypercoagulable states. Fundamental aspects, acquired disorders and congenital Thrombophilia. Boca Raton e. a.: CRC Press, 1996. 462 p.
30. Баркаган З. С. Гипергомоцистеинемия: частота, возрастные особенности, методы коррекции у больных коронарной болезнью сердца / З. С. Баркаган, Г. И. Костюченко, Л. А. Костюченко // Тромбоз, гемостаз, реология. – 2003. – № 3. – С. 33–36.
31. Рудницкая Т. А. Частота, значимость и коррекция гипергомоцистеинемии при сахарном диабете 2 типа: Автореф. дис.… канд. мед. наук / Т. А. Рудницкая. – Барнаул, 2003. – 22 с.
32. Сидоренко Г. И. Роль гомоцистеина в тромбо- и атерогенезе. Возможности и перспективы витаминной коррекции / Г. И. Сидоренко [и др.] // Кардиология. – 2001. – № 3. – С. 56–61.
33. Шмелева В. М. Гипергомоцистеинемия и тромбоз / В. М.Шмелева //Тромбоз, гемостаз и реология. – 2000. – № 4. – С. 26–29.
34. Carais P., Alberto M. F., Gennari L. C. et al. Antiphospholipid antibodies and hyperhomocysteinemia response to therapy with folic acid // J. Thromb. Haemost. 2003. Abstr. PO 421 (Poster).
35. Clarke R., Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice // Am. Clin. Biochem. 2001. Vol. 38. P. 624–632.
36. Malinovv M. R., Rang S. S., Taylor L. M. et al. Prevalence of hyperhomocysteinemia in patients with peripheral occlusive disease // Circulation. 1989. Vol. 79. P. 1180–1188.
37. Костюченко Г. И. Гипергомоцистеинемия при коронарной болезни сердца: Дис. ... д-ра мед. наук / Г. И. Костюченко. – Барнаул, 2004. – 139 с.
38. Albert M. A., Danielson E., Rifai N. et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation (CRP evalution (RPINCE)): a rand omized trial and cohort study // JAMA. 2001. Vol. 286. P. 4–70.
39. Fuster V., Corti R., Fayad Z. A. et al. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombotic and acute coronary syndromes // J. Thromb. Haemost. 2003. Vol. 1 (7). P. 1410–1421.
40. Hermander-Perera O., Perez-Sala D., Navarro-Antolin J. et al. Effects of the 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells // J. Clin. Invest. 1998. Vol. 101. P. 2711–2719.
41. Koh K. K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability // Cardivasc. Res. 2000. Vol. 47. P. 648–657.
42. Lancer P., Topol E. J., eds. Pan Vascular Medicine. Integrated Clinical Management. Berlin с. a: Springer Verlag, 2002. 1941 p.
43. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes // Circulation. 2001. Vol. 104. P. 365–372.
44. Ridker P. M., Rifai N., Clearfield M. et al. Air-Force: Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events // N. Engl. J. Med. 2001. Vol. 344. P. 1959–1965.
45. Rosenson R. S., Tangey E. C., Casecy L. C. Inhibition of proinflammatory cytokine production by pravastatin // Lancet. 1999. Vol. 353. P. 983–984.
46. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease // Lancet. 1994. Vol. 344. P. 1383–1389.
47. Seeger H., Mueck A. D., Lippert Т. Н. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells // Int. J. Pharmacol. Ther. 2000. Vol. 38. P. 270–272.
48. Shah P. K. New insights into the pathogenesis and prevention of acute coronary syndromes // Amer. J. Cardiol. 1997. Vol. 79. P. 17–23.
49. Undas A., Celinska-Lirwenhoff M., Kaczor M., Musial J. New nonlipid effects of statin and their clinical relevance in cardiovascular disease // Thromb. Haemost. 2004. Vol. 91 (6). P. 1065–1077.
50. Wassmann S., Laufs U., Mueller K. et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo // Arterioscler. Thromb. Vasс. Biol. 2002. Vol. 105. P. 933–938.
51. Ross R. Atherosclerosis — an inflammatory disease // N. Engl. J. Med. 1999. Vol. 340. P. 115–126.
52. Сулодексид. Механизмы действия и опыт клинического применения / Под ред. A. M. Светухина, З. С. Баркагана. – М., 2000. – 118 c.
53. Шустов С. В. Контролируемое клиническое исследование эффективности и безопасности сулодексида у больных с периферической окклюзивной артериопатией / С. В. Шустов; Ред. A. M. Светухин, З. С Баркаган // Сулодексид. – М., 2000. – C. 76–88.
54. Condorelli M., Ogiariello M., Dagianati A. et al. IPO-V2: A prospective, multicenter, randomized, comparative, clinical investigation of the effects of sulodexide in preventing cardiovascular accidents after acute myocardial infarction // J. Amer. Coll. Cardiol. 1994. Vol. 23 (1). P. 27–34.
55. Crowder J. E., Cohn J. B., Savitsky J. P. et al. Efficacy and safety of pentoxyfyllin in heriatric patients with intermittent claudication // Angiolgy. 1989. Vol. 40. P. 795–802.
56. Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutarie coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels // Circulation. 2001. Vol. 103. P. 1933–1935.
57. Parodi F. A., Cataldi L. Sulodexide activity in peripheral vascular diseases of diabetic patients // Gerontol. 1985. Vol. 33. P. 237–242.
58. Utratova J., Mayer J., Elbi L. et al. Experience with the preparation Sulodexide (Vessel Due F) in diabetics with ischemic affection of the lower extremities // Vnitr. Lek. 1993. Vol. 39 (6). P. 575–580.
59. Berkowitz S. D., Marder V. J., Kosutic Y., Bauchman R. A. Oral heparin administration with a novel drug deli very agent (SNAC) // J. Thromb. Haemost. 2003. Vol. 1 (9). P. 1914–1919.
60. Uchiba M., Okajama K. Antithrombin III prevents LPS-induced vascular injury: novel biological activity of AT HI.Thromb // Haemost. 1997. Vol. 23. P. 583–590.
61. Korthuis R. J., Gute D. C. Adhesion molecule expression in microvascular dysfunction: activity of a micronized purified flavonoid fraction // J. Vasс. Res. 1999. Vol. 36. (Suppl. 1). P. 15–23.
62. Shoab S. S., Porter J., Scurr Y. H. et al. Endothelial activation response to oral micronized flavonoid therapy in patients with chronic venous disease — a prospective study // Europ. J. Vasс. Endovasc. Surg. 1999. Vol. 17 (4). P. 313–318.
63. Shoab S. S., Porter J. B., Scurr J. H. et al. Effect of oral micromized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease — a pilot study // J. Vasс. Surg. 2000. Vol. 31 (3). P. 456–461.
64. Galley P., Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction in the treatment of symptomatic capillary fragility // Int. Angiol. 1993. Vol. 12 (1). P. 69–72.
Review
For citations:
Kostyuchenko G.I., Nikitin Yu.P., Arzamastsev D.D., Ananiev D.A., Tsalikhin A.D., Kostyuchenko L.A. Atherothrombosis: role of chronic vascular inflammation. Ateroscleroz. 2011;7(2):49-56. (In Russ.)
Views:
232
Email this article 